
A lawsuit alleges that Silicon Valley Bank’s parent company did not disclose risk to investors.
The class-action complaint alleges that because of failure to disclose risk, the plaintiffs were damaged when SVB Financial Group sold its securities at “artificially inflated prices” and later released an “alleged corrective disclosure.”
The suit was filed Monday (March 13) in U.S. District Court, Northern District of California, on behalf of people who purchased the company’s publicly traded securities between June 16, 2021, and March 10, 2023.
It names as defendants SVB Financial Group, SVB CEO Greg W. Becker and SVB Chief Financial Officer Daniel Beck.
Read more: Silicon Valley Bank’s UK Unit Saved by HSBC in Rapid Overnight Rescue Deal
The suit alleges that in several filings with the Securities and Exchange Commission (SEC), the defendants did not disclose the risk that future interest rate hikes posed to the company’s business, that it would be worse off than other banks in an environment of high interest rates, and that it was particularly susceptible to a bank run if its investments were negatively impacted by high interest rates.
“As a result, defendants’ public statements were materially false and/or misleading at all relevant times,” the suit said.
Then, in a March 8 press release, SVB announced that it sold $21 billion of securities in a move that would cause an after-tax loss of $1.8 billion, according to the suit.
This, in turn, triggered concerns among clients, a plunge in its share price and a liquidity crisis, the suit said.
“It quickly emerged that the culprit behind the liquidity crisis that caused SVB’s eventual collapse was rapidly rising interest rates,” the suit said.
Featured News
Trump Administration Steps Up Pressure On EU Digital Laws
May 18, 2025 by
CPI
Elton John Slams UK Government’s AI Copyright Plan as ‘Theft’
May 18, 2025 by
CPI
Anthropic’s Legal Team Blames AI “Hallucination” for Citation Error in Copyright Lawsuit
May 18, 2025 by
CPI
Intel Challenges €376 Million EU Antitrust Fine in Ongoing Legal Battle
May 18, 2025 by
CPI
FTC Chairman Highlights Fiscal Responsibility and Consumer Protection in House Testimony
May 18, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas